Abstract
In a phase II single-arm study, the PD-1 checkpoint inhibitor pembrolizumab effectively shrank tumors and prolonged survival in more than half of patients with Merkel cell carcinoma. Responses were significantly more durable that those typically seen with chemotherapy.
- ©2016 American Association for Cancer Research.
June 2016
Volume 6, Issue 6
Volume 6, Issue 6
Pembrolizumab Yields Lasting Merkel Cell Carcinoma Responses
Jump to section
Advertisement